| Current Price | $36.27 | Mkt Cap | $1.5B |
|---|---|---|---|
| Open | $35.34 | P/E Ratio | 0.00 |
| Prev. Close | $36.27 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $34.55 - $36.47 | Volume | 580,420 |
| 52-Wk Range | $25.93 - $50.26 | Avg. Daily Vol. | 345,982 |
| Current Price | $36.27 | Mkt Cap | $1.5B |
|---|---|---|---|
| Open | $35.34 | P/E Ratio | 0.00 |
| Prev. Close | $36.27 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $34.55 - $36.47 | Volume | 580,420 |
| 52-Wk Range | $25.93 - $50.26 | Avg. Daily Vol. | 345,982 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about RGNX.
Recs
tking123
(66.06)
Submitted: 1/8/2021 12:55:00 PM :
Start Price:
$47.21
NASDAQ:RGNX Score:
-34.32
Small company targeting eye disease gene therapy. Its eye-disease treatment is being tested in people with wet age-related macular degeneration. This is a big market and the leaders are Roche and Regeneron Pharmaceuticals.....Keep an eye on this one.
Recs
findil
(90.68)
Submitted: 9/27/2018 12:08:01 PM :
Start Price:
$76.70
NASDAQ:RGNX Score:
-97.46
Love the optionality of partners and internal pipeline combined with a differentiated competitive advantage.
Recs
TMFEBCapital
(97.32)
Submitted: 7/12/2018 12:41:22 PM :
Start Price:
$74.85
NASDAQ:RGNX Score:
-102.96
Big risk, big reward. Data from phase 1 trials in wet AMD and HoFH are on tap later this year. Solid balance sheet helped by $100 million payment in June from Novartis tied to NVS acquisition of AveXis, which is developing AVXS-101, an SMA gene therapy using RGNX's viral vectors.
Find the members with the highest scoring picks in RGNX.
otherAquanaut (99.68) Score: +172.80
The Score Leader is the player with the highest score across all their picks in RGNX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| otherAquanaut | 99.68 |
|
|
3M | $9.61 | +277.42% | +104.61% | +172.80 | 0 Comment | |
| portefeuille | 98.38 | 3/24/2016 |
|
5Y | $9.85 | +268.22% | +108.38% | +159.84 | 0 Comment | |
| portefeuille2 | 98.83 | 9/12/2016 |
|
5Y | $12.82 | +182.92% | +98.75% | +84.17 | 0 Comment | |
| clangmead | 48.27 | 9/12/2016 |
|
5Y | $12.82 | +182.92% | +98.75% | +84.17 | 1 Comment | |
| efarev | 64.46 | 5/23/2017 |
|
5Y | $18.60 | +95.00% | +75.86% | +19.14 | 0 Comment | |
| kkconway | 99.01 | 4/26/2021 |
|
5Y | $35.53 | +2.08% | +1.06% | +1.02 | 0 Comment | |
| naughtyguy | 32.79 | 5/7/2021 |
|
5Y | $35.34 | +2.63% | +0.53% | -2.10 | 0 Comment | |
| StockFlyer | 43.35 | 9/21/2020 |
|
5Y | $29.83 | +21.59% | +29.60% | -8.01 | 0 Comment | |
| Stlongs | 36.96 | 8/17/2020 |
|
5Y | $32.06 | +13.13% | +24.89% | -11.76 | 0 Comment | |
| TMFSaintCroix | 99.70 | 1/22/2018 |
|
5Y | $27.15 | +33.59% | +49.79% | -16.20 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
